16:08 EDT Exelixis (EXEL) still sees FY25 revenue $2.25B-$2.35B, consensus $2.34B
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis options imply 6.9% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, July 28, 2025
- EXEL Upcoming Earnings Report: What to Expect?
- Pan Tumor Rollover Study: A Key Update for Investors in Cancer Therapies
- Exelixis Advances Cancer Treatment with New Phase 1 Study of XB628